EDX Medical Group, the Cambridge-based diagnostics company that moved to AIM in May 2026, appeared among the most volatile UK stocks on 23 September 2026. A new employee-screening contract with Arnold Clark, a fresh Equity raise and a high-profile prostate cancer testing programme have given the shares plenty of news to digest.
EDX Medical Group plc (LSE:EDX) appeared among the most volatile UK stocks on 23 September 2026. The company's shares began trading on AIM on 13 May 2026 after moving from the Apex segment of the Aquis Stock Exchange Growth Market. This article uses the FTSE AIM All-Share as a backdrop and does not claim verified index constituency.
EDX develops diagnostic tests and services for cancer, infectious disease and wider health screening, operating from a laboratory in Cambridge. It was founded by biotech Entrepreneur Professor Sir Chris Evans. Revenue is still modest, so each new contract or funding announcement can shift how investors value the business.
Why EDX Medical Group (EDX) Is in Focus
The most recent catalyst came on 17 September 2026, when EDX announced a three-year employee health contract with the Arnold Clark Group, starting in October 2026. The company said it projects annual revenues of £1.4m to £1.6m from the agreement, which offers voluntary testing to Arnold Clark's 11,600 employees across 200 UK locations.
That followed full-year results published on 3 September, a £2.7m equity raise announced on 24 August and an update on the Scottish Prostate Cancer Initiative on 27 August. For a company with annual revenue of £330,000 in its latest financial year, a contract of that projected size is material news.
What Does EDX Medical Group Do?
EDX describes itself as developing digital diagnostic products and services that support personalised treatment for cancer and infectious diseases. Its activities include laboratory assays for early cancer detection and a patent-pending multiplex point-of-care test platform, and it has distribution arrangements with Caris Life Sciences and Curesponse.
Recent launches include testicular and bowel cancer testing services, a rapid pneumonia test developed with the University of Cambridge, Cambridge University Hospitals NHS Foundation Trust and the UK Health Security Agency, and an employee health screening service. The Arnold Clark contract covers biomarker panels spanning more than 220 conditions, including cancer, cardiovascular and metabolic disorders.
What Has Been Happening Recently?
On 25 March 2026 EDX was named lead delivery partner for the Scottish Prostate Cancer Initiative, founded by Olympian Sir Chris Hoy, which aims to test 25,000 men. On 27 August the company said more than 12,500 men had been tested in Phase 1 between March and June, and that 31 Phase 2 sessions running from August to November were almost fully booked.
Other milestones followed the AIM move. On 8 July EDX signed a service agreement with Astron Health, on 15 July it launched its employee health screening service, on 21 July it fully launched its BC95 bowel cancer testing service and on 3 August it said its rapid pneumonia test had been deployed for NHS patients. On 24 August it raised £2.7m by issuing 19,378,563 new shares at 14p to support the employee screening expansion, taking the share count to 431,373,146.
What Are the Numbers Saying?
For the year to 31 March 2026, EDX reported revenue of £330,000 and a loss of £5.7m, compared with a £3.7m loss a year earlier. Administrative expenses rose to £5.49m from £4.38m as the company invested in its team and technology. It raised £5.5m through share issues during the year, including a £3.5m fundraise announced in February 2026, before the further £2.7m after the period end.
The Arnold Clark contract's projected £1.4m to £1.6m in annual revenue is a company estimate that depends on employee take-up, since participation is voluntary. Chairman Jason Holt said the company has a high degree of confidence about the future, while acknowledging that commercial operations are at an early stage.
Why Is the Share Price Attracting Attention?
The facts: EDX is a recently admitted AIM company with early-stage revenue, continuing losses and a record of regular equity raises. In July 2026 the shares were around 10p and a Market Value of roughly £43m, with a 52-week range of 7.5p to 13.25p.
One possible interpretation of the Volatility is that the market is repricing EDX as it moves towards multi-year corporate contracts. Some investors may view the Arnold Clark agreement, and the company's statement in August that three UK employers had signed agreements in principle, as evidence of commercial traction; others may focus on the cash burn and the likelihood of further fundraising. The high profile of the prostate cancer initiative may also bring the shares to a wider retail audience.
How Does the FTSE AIM All-Share Context Matter?
Moving from Aquis to AIM gives EDX access to a larger pool of investors and potentially greater liquidity, but it also places the shares among a broad set of small healthcare and diagnostics names that are often sensitive to funding conditions. There is no evidence that FTSE AIM All-Share movements drove EDX's recent share price; the stock's moves appear more closely linked to its own contract and funding announcements.
What Could Investors Watch Next?
Several dated items may influence sentiment:
- AGM on 28 September 2026: the Annual General Meeting in London may bring an update on trading and contracts.
- Arnold Clark roll-out: testing is due to begin at Arnold Clark premises in October 2026, with uptake central to the revenue projection.
- Other employer agreements: whether the agreements in principle mentioned in August convert into signed contracts, with testing expected to begin in the fourth quarter of 2026.
- Scottish Prostate Cancer Initiative: completion of Phase 2 sessions by November and any published findings.
- Interim results: figures for the six months to 30 September 2026; last year's interims were published on 19 December.
The Bottom Line
EDX Medical Group's appearance among the most volatile UK stocks comes after a busy few months following its May move from Aquis to AIM. The company reported just £330,000 of revenue and a £5.7m loss for the year to March 2026, but has since launched new testing services, raised £2.7m and signed a three-year Arnold Clark contract it projects could bring £1.4m to £1.6m a year. That combination of small current revenue and potentially significant contracts can produce sharp swings in sentiment. What matters next is how quickly contracted testing converts into recognised revenue and whether further funding is needed.






Please wait processing your request...